ATE196315T1 - Interleukin-15 - Google Patents

Interleukin-15

Info

Publication number
ATE196315T1
ATE196315T1 AT94915781T AT94915781T ATE196315T1 AT E196315 T1 ATE196315 T1 AT E196315T1 AT 94915781 T AT94915781 T AT 94915781T AT 94915781 T AT94915781 T AT 94915781T AT E196315 T1 ATE196315 T1 AT E196315T1
Authority
AT
Austria
Prior art keywords
polypeptides
derivatives
interleukin
mammalian
etf
Prior art date
Application number
AT94915781T
Other languages
English (en)
Inventor
Kenneth H Grabstein
Dirk M Anderson
June R Eisenman
Charles Rauch
Victor Fung
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Priority claimed from ZA942636A external-priority patent/ZA942636B/xx
Application granted granted Critical
Publication of ATE196315T1 publication Critical patent/ATE196315T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94915781T 1994-04-06 1994-04-06 Interleukin-15 ATE196315T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NZ266264A NZ266264A (en) 1994-04-06 1994-04-06 Mammalian epithelium-derived t-cell factor called interleukin-15
PCT/US1994/003793 WO1995027722A1 (en) 1994-04-06 1994-04-06 Interleukin-15
ZA942636A ZA942636B (en) 1994-04-06 1994-04-18 Interleukin-15
OA60897A OA10375A (en) 1994-04-06 1996-09-27 Interleukin-15

Publications (1)

Publication Number Publication Date
ATE196315T1 true ATE196315T1 (de) 2000-09-15

Family

ID=33314371

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94915781T ATE196315T1 (de) 1994-04-06 1994-04-06 Interleukin-15

Country Status (11)

Country Link
EP (1) EP0772624B1 (de)
AT (1) ATE196315T1 (de)
CA (1) CA2186747C (de)
DE (1) DE69425906T2 (de)
DK (1) DK0772624T3 (de)
ES (1) ES2151927T3 (de)
GR (1) GR3035019T3 (de)
NZ (1) NZ266264A (de)
OA (1) OA10375A (de)
PT (1) PT772624E (de)
WO (1) WO1995027722A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE221784T1 (de) * 1995-04-02 2002-08-15 Chugai Pharmaceutical Co Ltd Arzneimittel zur heilung von thrombozytopenie
WO1997014433A1 (en) 1995-10-17 1997-04-24 Wayne State University Chicken interleukin-15 and uses thereof
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
US6451308B1 (en) 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
EP1627918A1 (de) * 1996-04-26 2006-02-22 Beth Israel Deaconess Medical Center, Inc. Interleukin-15 Antagonisten
US6001973A (en) * 1996-04-26 1999-12-14 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
US6087172A (en) * 1997-10-31 2000-07-11 Hisamitsu Pharmaceutical Co., Inc. Ribozymes targeted to human IL-15 mRNA
US5985663A (en) * 1998-11-25 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of interleukin-15 expression
WO2000050569A1 (en) * 1999-02-24 2000-08-31 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
US6828147B1 (en) 1999-02-24 2004-12-07 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
BR0110779A (pt) 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
CU23093A1 (es) * 2002-10-09 2005-10-19 Ct Ingenieria Genetica Biotech Composición vacunal que comprende interleucina-15 (il-15)
CN100427597C (zh) * 2003-11-26 2008-10-22 中国医学科学院基础医学研究所 可用于生产人重组白细胞介素-15的原核表达工程菌及纯化方法
CU23472A1 (es) 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
PT1809321E (pt) * 2004-10-08 2012-05-17 Us Gov Health & Human Serv Imunoterapia adotiva com sobrevivência aumentada de linfócitos
EP3263581B2 (de) 2005-05-17 2025-07-09 University of Connecticut Zusammensetzungen und verfahren zur immunmodulation in einem organismus
EP1777294A1 (de) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi Domäin als selektieve und potente Enhancer von IL-15 Aktion durch IL-15Rbeta/gamma, und Hyperagonist (IL15Ralpha sushi -IL15) Fusionsproteine
MX357691B (es) 2006-01-13 2018-07-19 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Il-15 y il-15r-alfa mejoradas para expresion en celulas mamiferas.
ES2642008T3 (es) 2007-05-11 2017-11-14 Altor Bioscience Corporation Moléculas de fusión y variantes de IL-15
AU2008269032B2 (en) 2007-06-27 2013-12-05 Novartis Ag Complexes of IL-15 and IL-15Ralpha and uses thereof
WO2009135031A1 (en) 2008-04-30 2009-11-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Substituted il-15
NZ714757A (en) 2009-08-14 2018-07-27 Us Gov Health & Human Services Use of il-15 to increase thymic output and to treat lymphopenia
CN102625832A (zh) 2009-08-24 2012-08-01 贝勒医学院 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系
EP3851459B1 (de) 2010-09-21 2024-05-01 Altor BioScience, LLC Multimere il-15-lösliche fusionsmoleküle sowie verfahren zu ihrer herstellung und verwendung
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
EP2537933A1 (de) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Auf IL-15- und IL-15Ralpha-Sushi-Domäne basierende Immunozytokine
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2791322A1 (de) 2011-12-12 2014-10-22 Cell Medica Limited Verfahren zur expansion von t-zellen
DK2812431T3 (da) 2012-02-09 2019-10-14 Baylor College Medicine Peptidblandinger til generering af multivirale ctl'er med bred specificitet
WO2014170032A1 (en) 2013-04-19 2014-10-23 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
EP2915569A1 (de) 2014-03-03 2015-09-09 Cytune Pharma Reinigungsverfahren für Il-15/Il-15Ralpha-basierte Konjugate
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
KR102762243B1 (ko) 2014-06-30 2025-02-05 알토 바이오사이언스 엘엘씨 Il-15-베이즈드 분자 및 이의 사용 방법
CA2998649A1 (en) 2015-09-18 2017-03-23 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
EP3468581A1 (de) 2016-06-13 2019-04-17 Torque Therapeutics, Inc. Verfahren und zusammensetzungen zur förderung der immunzellenfunktionen
EP3529263B1 (de) 2016-10-21 2025-08-06 Altor BioScience Corporation Multimere auf il-15-basierende moleküle
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CA3059634A1 (en) 2017-04-13 2018-10-18 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN119700941A (zh) 2017-05-15 2025-03-28 尼克塔治疗公司 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法
KR102008429B1 (ko) * 2017-06-30 2019-08-07 아주대학교산학협력단 인터루킨-15/인터루킨-15 수용체 알파-Fc 복합체를 포함하는 염증질환 치료 또는 예방용 조성물
EP3678701A4 (de) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. Therapeutische proteinzusammensetzungen und verfahren zur herstellung und verwendung davon
JP2022512766A (ja) 2018-10-17 2022-02-07 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN116981685A (zh) * 2020-12-03 2023-10-31 世纪治疗股份有限公司 基因工程化细胞及其用途
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b
US20250243279A1 (en) 2023-10-17 2025-07-31 Xencor, Inc. Bispecific antibodies that bind to nkp46 and mica/b

Also Published As

Publication number Publication date
WO1995027722A1 (en) 1995-10-19
GR3035019T3 (en) 2001-03-30
NZ266264A (en) 1997-01-29
DE69425906T2 (de) 2001-03-29
CA2186747C (en) 2009-01-27
DK0772624T3 (da) 2000-11-13
EP0772624B1 (de) 2000-09-13
EP0772624A1 (de) 1997-05-14
ES2151927T3 (es) 2001-01-16
CA2186747A1 (en) 1995-10-19
OA10375A (en) 2001-11-16
EP0772624A4 (de) 1997-07-02
PT772624E (pt) 2001-03-30
DE69425906D1 (en) 2000-10-19

Similar Documents

Publication Publication Date Title
ATE196315T1 (de) Interleukin-15
NO975437D0 (no) Nytt CD40L-mutein
DE69131580D1 (de) GDF-1 und UOG1 Proteine
MX9800719A (es) Proteinas de transporte y sus usos.
MX9503362A (es) Nuevos anticuerpos br96 mutantes y equivalentes funcionales que reaccionan con carcinomas humanos.
DE69725587D1 (de) Verwendung von wnt polypeptiden
DE69535147D1 (de) Überexpression von säugetier- und virusproteinen
DE69738586D1 (de) Hohe expressionsrate von proteinen
NO854460L (no) Syntetisk hepatitis-b-vaksine inbefattende baade t-celle og b-celledeterminanter.
MX9708426A (es) Polipeptido hk2 de variante estable.
DE59410132D1 (de) Humanes zirkulierendes cytokin cc-1
MX9702341A (es) Citoquina designada lerk-6.
SE9401380D0 (sv) Ny celltillväxt-relaterad peptid och användning därav
AU656353B2 (en) New variants derived from interferons of type I, production process thereof and their applications
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
EP0676413A3 (de) Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung.
NO974713D0 (no) Gener som koder for lymfocyttinterferon-regulatorisk faktor (LSIRF) polypeptider
AU4664489A (en) Ancrod proteins, their production and use
AU7378087A (en) Interleukin-2 induced antineoplastic peptide
AU1305097A (en) Protein induced by deprenyl$m(3)
ITMI931034A1 (it) Processo per la preparazione di proteine inibenti i ribosomi
ATE93893T1 (de) Expressionssysteme zur ueberproduktion gewuenschter proteine.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification